The Bolton Treo Endograft: A Single-Center Preliminary Experience.
Endovascular repair is currently the most frequently used treatment of abdominal aortic aneurysms, but its feasibility and success highly depend on the characteristics and the correct choice of the endograft to be used. Bolton Treo is one of the most popular endografts of newer generation which have been launched in the past few years, and this study aims to analyze the preliminary outcomes (8 months in average) of a single-center experience with this device. Thirty-seven consecutive abdominal aortic aneurysms, treated with Treo between June 2016 and December 2017, were followed up every 3, 6, and 12 months, and any kind of endograft-related complications was recorded. Technical success was 100%, and no perioperative death (within 30 days) was recorded. Over a mean follow-up period of 8 months, the overall reintervention rate was 5.4% (2 cases, for a type Ia endoleak and an iliac branch thrombosis), for those performed by endovascular techniques. Two type II endoleaks, not worthy of treatment, were also observed. No procedure-related mortality, endograft thrombosis, or rupture was observed. Over the short term, Treo demonstrated high effectiveness in treating abdominal aortic aneurysms both in elective and urgent settings, within and outside the indications for use. Outcomes over long term are still needed to validate these results.